Canaccord raises target for Pulse Biosciences stock from USD 43.00 to USD 58.00

Published on 10/07/2026 at 08:29 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Pulse Biosciences posted USD 0.43 million revenue in the second quarter. Pulse Biosciences stock was EUR 44.30 on October 7, 2026 versus EUR 44.20.

PLSE, US74587B1017, Illustration mit AI erstellt.

Pulse Biosciences (ISIN US74587B1017) was trading at EUR 44.30 at Lang & Schwarz on October 7, 2026 at 8:26 a.m. CEST in pre-market dealings, plus 0.23 percent versus the prior close of EUR 44.20. On October 6, 2026, Canaccord raised its price target from USD 43.00 to USD 58.00 while maintaining a Buy rating, as Investing.com reported.

Canaccord lifts the valuation bar

The new target places Canaccord's valuation view above the average 12-month target of USD 50.20 tracked by MarketBeat on October 6, 2026. Seven firms cover the stock in that overview, with five Buy ratings, one Strong Buy rating and one Sell rating.

Canaccord's update followed a virtual non-deal roadshow with Chief Executive Officer Paul LaViolette and Chief Financial Officer Jon Skinner. The firm said its underlying estimates were unchanged, making the target revision primarily a valuation and comparison-group decision rather than a new earnings forecast.

Clinical progress meets financial pressure

Pulse Biosciences completed enrollment of 100 patients in the PRECISE-BTN study, expanded from an original 50-patient design across three U.S. clinical sites. The September 15, 2026 filing also said the first enrolled patient completed the final 12-month follow-up, while preliminary data are planned for a future medical society conference, according to the SEC filing.

The latest reported quarter ended June 30, 2026. Revenue was USD 0.43 million versus USD 0.53 million expected, while the reported loss was USD 0.36 per share against a consensus loss of USD 0.29, figures published by MarketBeat on October 6, 2026. The contrast is central to the valuation debate: clinical milestones are advancing, while commercial revenue remains early.

Stock stays below its yearly high

Pulse Biosciences had a market capitalization of USD 3.4 billion as of October 6, 2026. Its primary Nasdaq listing showed a 52-week range of USD 12.56 to USD 58.90, placing the latest U.S. market value below the yearly high while the euro quote remained positive against its prior close.

At Lang & Schwarz, Pulse Biosciences stock was trading at EUR 44.30 on October 7, 2026 at 8:26 a.m. CEST, plus 0.23 percent versus the Lang & Schwarz prior close of EUR 44.20. The further course of trading is shown by the continuously updated real-time quote of Pulse Biosciences stock.